Background The increasing prevalence of polypharmacy has raised concerns about drug-drug interactions (DDIs) and their impact on patient safety. Database-based DDI detection often suffers from insufficient patient background information and missing data, limiting the accuracy and applicability of DDI assessments. A novel model is needed to overcome these limitations and provide a more comprehensive evaluation of DDIs to enhance patient safety in the context of multiple medication use. Objectives This study aims to develop and validate a novel model for evaluating both the beneficial and detrimental effects of DDIs on patient safety. The model is designed to address challenges associated with insufficient patient background information and missing data in database studies while providing a comprehensive assessment of DDIs using statistical inference and hypothesis tests. Methods To address the challenges of insufficient patient background information and missing data often encountered in database studies, the proposed model incorporates an overlap parameter. This parameter represents the degree of commonality in patient profiles susceptible to adverse events from individual drug administrations. The magnitude of DDIs is presented in a 2×2 contingency table constructed by the occurrence or non-occurrence of specific adverse events in observed value and expected value estimated from the model. This tabular format facilitates the assessment of DDIs using statistical inference and hypothesis tests. Results Simulations under various settings confirmed that significance levels for statistical hypothesis tests were strictly observed. Furthermore, applications to real-world databases demonstrated that the proposed model effectively identifies both positive and negative DDIs. Conclusions This research provides healthcare professionals with a robust and practical tool for enhanced DDI detection and management. The presentation of findings in a familiar 2×2 contingency table format improves the accessibility of our results, facilitating straightforward interpretation. The proposed model has the potential to promote a safer healthcare environment for patients on multiple medications, ultimately enhancing patient safety and treatment efficacy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893214PMC
http://dx.doi.org/10.7759/cureus.78746DOI Listing

Publication Analysis

Top Keywords

patient safety
16
insufficient patient
12
patient background
12
background missing
12
missing data
12
hypothesis tests
12
proposed model
12
beneficial detrimental
8
drug-drug interactions
8
patient
8

Similar Publications

Design: Platelet-rich plasma (PRP) is a popular treatment option in managing chronic tendinopathies, although the literature is inconsistent, mainly because of significant heterogeneity in patient populations. Patients who failed conservative management may respond differently than those who have not undergone first-line treatment. This systematic review and meta-analysis aimed to evaluate the efficacy of PRP injections in reducing pain and improving function in patients with chronic tendinopathy who failed conservative treatment.

View Article and Find Full Text PDF

Objectives: to map the scientific production on teaching-learning strategies related to patient safety in higher education institutions across Nursing, Pharmacy, Medicine, and Dentistry programs.

Methods: this scoping review follows the Joanna Briggs Institute (JBI) guidelines and the PRISMA Extension for Scoping Reviews recommendations. The selection of studies was performed using databases, grey literature, and reverse searching, conducted by two independent and blinded reviewers.

View Article and Find Full Text PDF

Assessment of patient safety from their perspective during the COVID-19 pandemic.

Rev Gaucha Enferm

March 2025

Universidade Federal de São Paulo (UNIFESP), Escola Paulista de Enfermagem. Departamento de Administração em Serviços de Saúde e Enfermagem. São Paulo, São Paulo, Brasil.

Objective: to assess patient safety, from their own perspective, during hospitalization for COVID-19 in a university hospital.

Method: cross-sectional study conducted in a university hospital in São Paulo, Brazil, involving patients hospitalized due to COVID-19. The sample included 129 participants hospitalized between March 2020 and June 2021 who responded to the Patient Measure of Safety instrument.

View Article and Find Full Text PDF

Individualized Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administration in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: The Nurse's Role.

J Infus Nurs

March 2025

Author Affiliations: Takeda Development Center Americas, Inc., Cambridge, Massachusetts (Kim Duff); IQVIA Clinical Research Organization, Milan, Italy (Arianna Soresini); IQVIA Clinical Research Organization, Cambridge, Massachusetts (Nancy Wolf* and Alane Fairchild); IQVIA Clinical Research Organization, Ankara, Turkey (Şükran Altan**); IQVIA Clinical Research Organization, Mexico City, Mexico (Wendy Bencomo); University Clinical Center of Serbia, Belgrade, Serbia (Ivana Ivankovic); University Health Network, University of Toronto, Toronto, Ontario, Canada (Evelyn Sarpong); IQVIA Clinical Research Organization, Warsaw, Poland (Anna Kuczkowska).

Hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% offers potential improvements in patient independence and tolerability versus intravenous immunoglobulin (IVIG) when used for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). fSCIG 10% also requires less frequent infusions and fewer infusion sites than conventional subcutaneous immunoglobulin (subcutaneous immunoglobulin without hyaluronidase). The ADVANCE-CIDP 1 study demonstrated fSCIG 10% efficacy and safety in preventing CIDP relapse and positive responses from patients in terms of satisfaction and treatment preference.

View Article and Find Full Text PDF

Purpose: To evaluate the occurrence of complications following intravitreal injections (IVIs) performed in an outpatient clean room (OCR) equipped with the mobile laminar airflow device (LAF) Operio.

Methods: This retrospective study analyzed the data of 10,016 IVIs performed in an OCR from April 2023 to November 2024. All information of each patient was registered, such as diagnosis, drug injected and any occurring complication or adverse events such as endophthalmitis, intraocular inflammation, rhegmatogenous retinal detachment (RRD), vitreous hemorrhages and elevated intraocular pressure.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!